Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0097
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know? ; volume:32 ; number:1 ; day:4 ; month:2 ; year:2021 ; pages:63-76 ; date:3.2021
Endocrine pathology ; 32, Heft 1 (4.2.2021), 63-76, 3.2021
- Urheber
-
Volante, Marco
Lam, Alfred K.
Papotti, Mauro
Tallini, Giovanni
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12022-021-09665-2
- URN
-
urn:nbn:de:101:1-2021050212405677205293
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Volante, Marco
- Lam, Alfred K.
- Papotti, Mauro
- Tallini, Giovanni
- SpringerLink (Online service)
Ähnliche Objekte (12)
FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale
Contrast-enhanced CT-based Radiomics for the Differentiation of Anaplastic or Poorly Differentiated Thyroid Carcinoma from Differentiated Thyroid Carcinoma: A Pilot Study
Genetic profiling of poorly differentiated sinonasal tumours
Poorly differentiated thyroid carcinoma : An underdiagnosed entity
MRI features of histological subtypes of thyroid cancer in comparison with CT findings: differentiation between anaplastic, poorly differentiated, and papillary thyroid carcinoma
Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion
Poorly differentiated carcinoma arising from adenolymphoma of the parotid gland
Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic)
Characterization of the genomic alterations in poorly differentiated thyroid cancer
FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale
Contrast-enhanced CT-based Radiomics for the Differentiation of Anaplastic or Poorly Differentiated Thyroid Carcinoma from Differentiated Thyroid Carcinoma: A Pilot Study
Genetic profiling of poorly differentiated sinonasal tumours
Poorly differentiated thyroid carcinoma : An underdiagnosed entity
MRI features of histological subtypes of thyroid cancer in comparison with CT findings: differentiation between anaplastic, poorly differentiated, and papillary thyroid carcinoma
Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion
Poorly differentiated carcinoma arising from adenolymphoma of the parotid gland
Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic)
Characterization of the genomic alterations in poorly differentiated thyroid cancer
FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale
Contrast-enhanced CT-based Radiomics for the Differentiation of Anaplastic or Poorly Differentiated Thyroid Carcinoma from Differentiated Thyroid Carcinoma: A Pilot Study
Genetic profiling of poorly differentiated sinonasal tumours
Poorly differentiated thyroid carcinoma : An underdiagnosed entity
MRI features of histological subtypes of thyroid cancer in comparison with CT findings: differentiation between anaplastic, poorly differentiated, and papillary thyroid carcinoma
Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion
Poorly differentiated carcinoma arising from adenolymphoma of the parotid gland
Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic)